论文部分内容阅读
本研究对６０例鼻咽癌患者采用双盲随机分组法，对服用复春片合并放射治疗鼻咽癌的预后进行了前瞻性对照研究。结果提示，两组患者的１、３、５年生存率无显著性差异，而服用复春片组患者的肿瘤血性转移率（３６．７％）高出对照组患者（１０．０％）２．６７倍，提示在现有剂量条件下，复春片对鼻咽癌细胞可能尚无明显放射增敏作用。因而认为不宜将复春片常规单独或与放射合并应用治疗鼻咽恶性肿瘤。
In this study, 60 patients with nasopharyngeal carcinoma by double-blind randomized group of patients taking Fuchun tablets combined with radiotherapy for the prognosis of nasopharyngeal carcinoma prospective controlled study. The results showed that there was no significant difference in 1, 3 and 5-year survival rate between the two groups, while the rate of hematogenous metastasis (36.7%) in patients taking Fuchun Tablets was significantly higher than that in the control group (10.0%) 2 .67 times, suggesting that under the existing dose conditions, Fuchun tablets on nasopharyngeal carcinoma cells may not have significant radiosensitization. Therefore, it is not appropriate to rejuvenation tablets routinely alone or combined with radiation treatment of nasopharyngeal malignant tumors.